# 21 U.S.C. 355-2 Actions for delays of generic drugs and biosimilar biological products

21 U.S.C. 355-2 Actions for delays of generic drugs and biosimilar biological products, “Actions for delays of generic drugs and biosimilar biological products”, is a U.S. Code section of [Part A—Drugs and Devices](https://ontology.bommaritollc.com/id/01a0f06c-cb97-754b-b68a-a66a473f5a0d); in force.

IRI: <https://ontology.bommaritollc.com/id/01a0f06c-ccd8-745e-84b4-4a4530dbb4da>

Within: [Title 21—Food and Drugs](https://ontology.bommaritollc.com/id/01a0f06c-cb65-7672-8fda-c39517ff08c0) › [Chapter 9—Federal Food, Drug, and Cosmetic Act](https://ontology.bommaritollc.com/id/01a0f06c-cb91-72e0-858b-060e8c845f23) › [Subchapter V—Drugs and Devices](https://ontology.bommaritollc.com/id/01a0f06c-cb96-7040-b454-c8f18e0e95cb) › [Part A—Drugs and Devices](https://ontology.bommaritollc.com/id/01a0f06c-cb97-754b-b68a-a66a473f5a0d)

Type: [schema:Legislation](https://schema.org/Legislation)

- `adms:identifier`: [usc-section 21 U.S.C. 355-2](https://ontology.bommaritollc.com/id/01a0f06c-ccd9-779c-b02d-f70d193e503c)
- `eli:cites`:
  - [15 U.S.C. 12 Definitions; short title](https://ontology.bommaritollc.com/id/01a0ee1d-4a12-72f7-9299-823c5dcfd0e0)
  - [15 U.S.C. 45 Unfair methods of competition unlawful; prevention by Commission](https://ontology.bommaritollc.com/id/01a0ee1d-4aa7-732e-9a3e-97f9a5a1d7d7)
  - [21 U.S.C. 321 Definitions; generally](https://ontology.bommaritollc.com/id/01a0f06c-cc8c-7030-ab68-1def0b197dcb)
  - [21 U.S.C. 355 New drugs](https://ontology.bommaritollc.com/id/01a0f06c-ccd6-7038-b7ea-5f9e1b3b3f50)
  - [21 U.S.C. 355-1 Risk evaluation and mitigation strategies](https://ontology.bommaritollc.com/id/01a0f06c-ccd7-7652-842e-3b43e4a564b5)
  - [21 U.S.C. 356e Drug shortage list](https://ontology.bommaritollc.com/id/01a0f06c-ccee-7344-b4b7-63434c7ace97)
  - [42 U.S.C. 262 Regulation of biological products](https://ontology.bommaritollc.com/id/01a0f07c-d9ca-7203-a1d8-2d79c0329140)
  - [42 U.S.C. 1395w-3a Use of average sales price payment methodology](https://ontology.bommaritollc.com/id/01a0f07c-e101-77ca-9302-626ce27357ac)
- `prov:wasDerivedFrom`:
  - [evidence from https://www.govinfo.gov/app/details/USCODE-2024-title21/USCODE-2024-title21-chap9-subchapV-partA-sec355-2](https://ontology.bommaritollc.com/id/01a0f06c-ccd8-745e-84b4-4a4450188ca4)
  - [evidence from https://www.govinfo.gov/app/details/](https://ontology.bommaritollc.com/id/01a0f06c-d14f-77b2-854b-a3084a0828a5)
  - [evidence from https://www.govinfo.gov/app/details/](https://ontology.bommaritollc.com/id/01a0f0d2-2d3b-7331-aeb0-0befca1b9564)
  - [evidence from https://www.govinfo.gov/link/uscode/21/355-2?type=usc&year=mostrecent&link-type=details](https://ontology.bommaritollc.com/id/01a10f15-fe21-7548-9995-5ae5d97b673d)
- `schema:isPartOf`: [Part A—Drugs and Devices](https://ontology.bommaritollc.com/id/01a0f06c-cb97-754b-b68a-a66a473f5a0d)
- `schema:legislationIdentifier`: 21 U.S.C. 355-2
- `schema:legislationJurisdiction`: [United States](https://ontology.bommaritollc.com/id/01a0ed8e-f797-7004-b7f5-bec2695977c0)
- `schema:legislationLegalForce`: [schema:InForce](https://schema.org/InForce)
- `schema:legislationType`: [U.S. Code section](https://ontology.bommaritollc.com/vocab/leg/uscSection)
- `schema:name`: Actions for delays of generic drugs and biosimilar biological products
- `schema:url`: [https://www.govinfo.gov/link/uscode/21/355-2?type=usc&year=mostrecent&link-type=details](https://www.govinfo.gov/link/uscode/21/355-2?type=usc&year=mostrecent&link-type=details)
- `skos:prefLabel`: 21 U.S.C. 355-2 Actions for delays of generic drugs and biosimilar biological products

## Elsewhere

- [Official page](https://www.govinfo.gov/link/uscode/21/355-2?type=usc&year=mostrecent&link-type=details) (www.govinfo.gov)
- [Source](https://www.govinfo.gov/app/details/USCODE-2024-title21/USCODE-2024-title21-chap9-subchapV-partA-sec355-2) (www.govinfo.gov)
- [Source](https://www.govinfo.gov/app/details/) (www.govinfo.gov)

## Pointing here

- Cited by (1; `eli:cites`):
  - [21 U.S.C. 355-1 Risk evaluation and mitigation strategies](https://ontology.bommaritollc.com/id/01a0f06c-ccd7-7652-842e-3b43e4a564b5)
- Its changes, from (1; `eli:changes`):
  - [Pub. L. 116-94](https://ontology.bommaritollc.com/id/01a0edf4-a3b8-7328-b6ed-cbc9034349cf)

---
Also as: [Turtle](https://ontology.bommaritollc.com/id/01a0f06c-ccd8-745e-84b4-4a4530dbb4da.ttl), [JSON-LD](https://ontology.bommaritollc.com/id/01a0f06c-ccd8-745e-84b4-4a4530dbb4da.jsonld), [N-Triples](https://ontology.bommaritollc.com/id/01a0f06c-ccd8-745e-84b4-4a4530dbb4da.nt), [HTML](https://ontology.bommaritollc.com/id/01a0f06c-ccd8-745e-84b4-4a4530dbb4da)
Cite as: 21 U.S.C. 355-2 Actions for delays of generic drugs and biosimilar biological products. bc-ontology, release 0.1.0-rc38, 2026-10-21. https://ontology.bommaritollc.com/id/01a0f06c-ccd8-745e-84b4-4a4530dbb4da
Release 0.1.0-rc38, graph hash 05350a11cf9d0c42fba51e92b877115781ab65cb92afcd6b172ff9f8f4abf0bd.
